CoChat

Use of Thiazolidinediones and the Risk of Colorectal Cancer in Patients With Diabetes

Open access
Chen, Shih-Wei, Tsan, Yu-Tse, Chen, Jong-Dar, Hsieh, Hui-I, Lee, Chang-Hsing, Lin, Hsien-Ho, Wang, Jung-Der, Chen, Pau-Chung, Health Data Analysis in Taiwan Research Group · 2013 · Diabetes Care

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Preclinical data suggest that peroxisome proliferator–activated receptor γ (PPARγ) agonists have antineoplastic effects in colorectal cancer. We aimed to assess the association between the use of synthetic PPARγ agonists, represented by thiazolidinediones (TZDs), and the risk of developing colorectal cancer. RESEARCH DESIGN AND METHODS: We conducted a nationwide, population-based, case-control study using the Taiwan National Health Insurance Research Database. Case subjects were defined as patients who were diagnosed with diabetes at least 365 days prior to a new diagnosis of colorectal cancer between 2000 and 2008. We randomly selected diabetic control subjects for each case subject, which were matched by sex, age, and the duration of diabetes. Among the 24,496 eligible case subjects and control subjects, we used conditional logistic regression to assess the risk of colorectal cancer in association with the use of TZDs. An additional analysis was conducted to assess the effects of concomitant use of TZDs and low-dose aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) on the risk of colorectal cancer. RESULTS: A decreased risk of colorectal cancer was observed in patients who had used TZDs compared with those who had never used TZDs (adjusted odds ratio 0.86 [95% CI 0.79–0.94]). Furthermore, the benefit of a decreased colorectal cancer risk was also found with concomitant use of TZDs and low-dose aspirin or NSAIDs. CONCLUSIONS: The use of TZDs may be associated with a decreased risk of colorectal cancer in patients with diabetes. Further studies are warranted to confirm our findings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc11-2197

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Adjusted ORs for colorectal cancer treated with a combination of TZDs and low-dose aspirin (A) or a combination of TZDs and NSAIDs (B). CRC, colorectal cancer. Group Ia, never used TZDs and the duration of low-dose aspirin use was <270 days; group IIa, duration of TZD use was between 1 and 270 days, and the duration of low-dose aspirin use was <270 days; group IIIa, duration of TZD use was >270 days, and duration of low-dose aspirin use was <270 days; group IVa, never used TZDs, and duration of low-dose aspirin use was >270 days; group Va, duration of TZD use was between 1 and 270 days, and the duration of low-dose aspirin use was > 270 days; group VIa, duration of TZD use was >270 days, and the duration of low-dose aspirin use was >270 days; group Ib, never used TZDs, and the duration of NSAID use was <90 days; group IIb, duration of TZD use was between 1 and 270 days, and the duration of NSAIDs use was <90 days; group IIIb, duration of TZD use was >270 days, and the duration of NSAID use was <90 days; group IVb, never used TZD, and the duration of NSAID use was >90 days; group Vb, duration of TZD use was between 1 and 270 days, and the duration of NSAID use was >90 days; group VIb, duration of TZD use was >270 days, and the duration of NSAID use was >90 days. *Adjusted for urbanization, income, colorectal polyp disorder, inflammatory bowel disease, hypertension, hyperlipidemia, biliary stone disease, alcohol-related disease, chronic kidney disease, diabetes-related complications, ischemic heart disease, cerebrovascular disease, heart failure, chronic obstructive pulmonary disease, and hormone therapy. P for interaction between low-dose aspirin and TZD = 0.854. P for interaction between NSAID and TZD = 0.781.
Figure 1 Adjusted ORs for colorectal cancer treated with a combination of TZDs and low-dose aspirin (A) or a combination of TZDs and NSAIDs (B). CRC, colorectal cancer. Group Ia, never used TZDs and the duration of low-dose aspirin use was <270 days; group IIa, duration of TZD use was between 1 and 270 days, and the duration of low-dose aspirin use was <270 days; group IIIa, duration of TZD use was >270 days, and duration of low-dose aspirin use was <270 days; group IVa, never used TZDs, and duration of low-dose aspirin use was >270 days; group Va, duration of TZD use was between 1 and 270 days, and the duration of low-dose aspirin use was > 270 days; group VIa, duration of TZD use was >270 days, and the duration of low-dose aspirin use was >270 days; group Ib, never used TZDs, and the duration of NSAID use was <90 days; group IIb, duration of TZD use was between 1 and 270 days, and the duration of NSAIDs use was <90 days; group IIIb, duration of TZD use was >270 days, and the duration of NSAID use was <90 days; group IVb, never used TZD, and the duration of NSAID use was >90 days; group Vb, duration of TZD use was between 1 and 270 days, and the duration of NSAID use was >90 days; group VIb, duration of TZD use was >270 days, and the duration of NSAID use was >90 days. *Adjusted for urbanization, income, colorectal polyp disorder, inflammatory bowel disease, hypertension, hyperlipidemia, biliary stone disease, alcohol-related disease, chronic kidney disease, diabetes-related complications, ischemic heart disease, cerebrovascular disease, heart failure, chronic obstructive pulmonary disease, and hormone therapy. P for interaction between low-dose aspirin and TZD = 0.854. P for interaction between NSAID and TZD = 0.781.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 38

Metadata

Authors
Chen, S.-W., Tsan, Y.-T., Chen, J.-D., Hsieh, H.-I., Lee, C.-H., Lin, H.-H., Wang, J.-D., Chen, P.-C., & Health Data Analysis in Taiwan Research Group
Affiliations
  • National Taiwan University (TW)
  • Fu Jen Catholic University (TW)
  • National Cheng Kung University (TW)
Corresponding author
Chen, Pau-Chung
Venue
Diabetes Care
Published
2013-01-17
Volume
36
Issue
2
Pages
369-375
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2098056191
Cited by
37
References
28
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 5 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 3 · 2015: 3 · 2014: 6 · 2013: 4
FWCI
1.56
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
Keywords
thiazolidinediones, colorectal cancer, diabetes mellitus, PPARγ agonists, cancer risk, aspirin, nonsteroidal anti-inflammatory drugs, chemoprevention
MeSH terms
Adult, Aged, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Colorectal Neoplasms, Case-Control Studies, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of Thiazolidinediones and the Risk of Colorectal Cancer in Patients With Diabetes. https://app.cochat.ai/papers/10.2337/dc11-2197
The paper
Chen, S.-W., Tsan, Y.-T., Chen, J.-D., Hsieh, H.-I., Lee, C.-H., Lin, H.-H., Wang, J.-D., Chen, P.-C., & Health Data Analysis in Taiwan Research Group. (2013). Use of Thiazolidinediones and the Risk of Colorectal Cancer in Patients With Diabetes. Diabetes Care. https://doi.org/10.2337/dc11-2197

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.